Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MediciNova, Inc. before investing.

In this article, we go over a few key elements for understanding MediciNova, Inc.’s stock price such as:

• MediciNova, Inc.’s current stock price and volume
• Why MediciNova, Inc.’s stock price changed recently
• Upgrades and downgrades for MNOV from analysts
• MNOV’s stock price momentum as measured by its relative strength

About MediciNova, Inc. (MNOV)

Before we jump into MediciNova, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Want to learn more about MediciNova, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MediciNova, Inc..

MediciNova, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, MediciNova, Inc.’s stock price was $1.450.

MediciNova, Inc. is 0% from its previous closing price of $1.450.

During the last market session, MediciNova, Inc.’s stock traded between $1.450 and $1.470. Currently, there are approximately 49.05 million shares outstanding for MediciNova, Inc..

MediciNova, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MediciNova, Inc. Stock Price History

MediciNova, Inc.’s (MNOV) price is currently down 12.65% so far this month.

During the month of November, MediciNova, Inc.’s stock price has reached a high of $1.690 and a low of $1.330.

Over the last year, MediciNova, Inc. has hit prices as high as $2.480 and as low as $1.130. Year to date, MediciNova, Inc.’s stock is down 30.95%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MediciNova, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 26, 2025,, no analysts have changed their rating of MediciNova, Inc.’s stock over the last month.

Additionally, you'll want to evaluate MediciNova, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MediciNova, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

MediciNova, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MediciNova, Inc. (MNOV) by visiting AAII Stock Evaluator.

Relative Price Strength of MediciNova, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, MediciNova, Inc. has a weighted four-quarter relative price strength of -7.58%, which translates to a Momentum Score of 33 and is considered to be Weak.

Want to learn more about how MediciNova, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MediciNova, Inc. Stock Price: Bottom Line

As of November 28, 2025, MediciNova, Inc.’s stock price is $1.450, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MediciNova, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.